Kathmere Capital Management’s Pfizer PFE Stock Holding History

Kathmere Capital Management’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.22M	Sell	50,687 -2,661	-5%	-$69.6K	0.06%	207
2026 Q1	$1.5M	Buy	53,348 +7,388	+16%	+$197K	0.09%	150
2025 Q4	$1.14M	Buy	45,960 +13,318	+41%	+$336K	0.08%	167
2025 Q3	$832K	Buy	32,642 +6,354	+24%	+$157K	0.06%	206
2025 Q2	$637K	Buy	26,288 +16,724	+175%	+$390K	0.05%	235
2025 Q1	$242K	Buy	+9,564	New	+$250K	0.02%	374
2024 Q2	–	Sell	-7,321	Closed	-$203K	–	353
2024 Q1	$203K	Buy	+7,321	New	+$203K	0.02%	303
2023 Q4	–	Sell	-11,460	Closed	-$380K	–	305
2023 Q3	$380K	Buy	11,460 +4,194	+58%	+$148K	0.06%	157
2023 Q2	$266K	Buy	+7,266	New	+$283K	0.04%	187
2023 Q1	–	Sell	-5,420	Closed	-$278K	–	243
2022 Q4	$278K	Sell	5,420 -368	-6%	-$17.6K	0.05%	152
2022 Q3	$253K	Buy	5,788 +584	+11%	+$28.4K	0.05%	135
2022 Q2	$273K	Buy	5,204 +439	+9%	+$22.4K	0.05%	136
2022 Q1	$247K	Buy	+4,765	New	+$247K	0.04%	150
2021 Q1	–	Sell	-1,653	Closed	-$61K	–	323
2020 Q4	$61K	Buy	1,653 +965	+140%	+$35.4K	0.01%	228
2020 Q3	$24K	Buy	+688	New	+$24.1K	0.01%	261

Other funds holding PFE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Kathmere Capital Management's PFE Position: Q2 2026 in Review

Kathmere Capital Management reduced its Pfizer (PFE) stake by 5% in Q2 2026, selling an estimated $69.6K and leaving 50,687 shares worth $1.22M. The position accounts for 0.06% of the portfolio, ranked #207.

Kathmere Capital Management first reported a position in PFE in Q3 2020 and has held it in 15 quarters since. The position peaked at $1.5M in Q1 2026. 2,822 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

Kathmere Capital Management held 50,687 shares of Pfizer worth $1.22M as of Q2 2026.
Kathmere Capital Management sold 2,661 Pfizer shares in Q2 2026, an estimated $69.6K.
Pfizer made up 0.06% of Kathmere Capital Management's portfolio in Q2 2026, its #207 holding.
Kathmere Capital Management first reported a position in Pfizer in Q3 2020 and has held it in 15 quarters since.
Kathmere Capital Management's Pfizer position peaked at $1.5M in Q1 2026.
2,822 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Kathmere Capital Management's 13F filing for Q2 2026, filed 29 Jul 2026.